Second, since study population was enrolled before angiotensin receptor neprilysin inhibitor and sodium glucose cotransporter 2 inhibitors were clinically applied for HF in Japan, we could not examine the impact of these medicines on malnutrition, renal dysfunction and clinical outcomes. This evidence concerns the gene SLC5A2 and Abnormal renal physiology.